Luoxin Pharmaceuticals Group Stock Co Ltd (002793) — Working Capital to Net Assets Ratio
Luoxin Pharmaceuticals Group Stock Co Ltd (002793) has a Working Capital to Net Assets ratio of -47.0% as of March 2026. Working capital of CN¥-552.24 Million (current assets of CN¥1.76 Billion minus current liabilities of CN¥2.31 Billion) is measured against net assets of CN¥1.18 Billion. A higher ratio indicates strong short-term liquidity financed by the equity base. See 002793 financial flexibility score to measure the company's free cash flow as a share of total liabilities.
WC/NA Ratio
Working Capital
Current Assets
Current Liabilities
Luoxin Pharmaceuticals Group Stock Co Ltd Working Capital to Net Assets (2011–2025)
This chart shows how Luoxin Pharmaceuticals Group Stock Co Ltd's Working Capital to Net Assets ratio has evolved across 15 annual periods from 2011 to 2025. As of March 2026, the ratio stands at -47.0%, reflecting working capital of CN¥-552.24 Million against net assets of CN¥1.18 Billion CNY. See Luoxin Pharmaceuticals Group Stock Co Lt (002793) defensive interval to measure how many days the company can operate on defensive assets alone.
Annual Working Capital to Net Assets for Luoxin Pharmaceuticals Group Stock Co Ltd (2011–2025)
The table below presents the year-by-year Working Capital to Net Assets ratio for Luoxin Pharmaceuticals Group Stock Co Ltd from 2011 to 2025, covering 15 annual filings. Each row shows current assets, current liabilities, working capital, net assets, the ratio, and the change in percentage points compared to the prior year. For live market cap and the full company profile, see 002793 company net worth.
| Year | WC/NA Ratio | Working Capital (CNY) | Net Assets | Current Assets | Current Liabilities | Change (pp) |
|---|---|---|---|---|---|---|
| 2025 | -29.9% | CN¥-369.11 Million | CN¥1.24 Billion | CN¥1.93 Billion | CN¥2.30 Billion | ▲ +21.8 pp |
| 2024 | -51.6% | CN¥-753.60 Million | CN¥1.46 Billion | CN¥1.78 Billion | CN¥2.54 Billion | ▼ -57.5 pp |
| 2023 | 5.8% | CN¥149.96 Million | CN¥2.57 Billion | CN¥2.07 Billion | CN¥1.92 Billion | ▼ -4.7 pp |
| 2022 | 10.5% | CN¥347.07 Million | CN¥3.31 Billion | CN¥4.72 Billion | CN¥4.37 Billion | ▼ -39.4 pp |
| 2021 | 49.9% | CN¥2.36 Billion | CN¥4.74 Billion | CN¥6.37 Billion | CN¥4.01 Billion | ▲ +5.9 pp |
| 2020 | 44.0% | CN¥1.91 Billion | CN¥4.35 Billion | CN¥4.88 Billion | CN¥2.97 Billion | ▼ -4.6 pp |
| 2019 | 48.5% | CN¥1.92 Billion | CN¥3.96 Billion | CN¥4.87 Billion | CN¥2.95 Billion | ▼ -14.1 pp |
| 2018 | 62.6% | CN¥570.01 Million | CN¥909.89 Million | CN¥817.23 Million | CN¥247.22 Million | ▲ +17.9 pp |
| 2017 | 44.7% | CN¥337.36 Million | CN¥754.19 Million | CN¥477.18 Million | CN¥139.82 Million | ▼ -14.6 pp |
| 2016 | 59.4% | CN¥414.53 Million | CN¥698.33 Million | CN¥526.40 Million | CN¥111.87 Million | ▲ +28.2 pp |
| 2015 | 31.1% | CN¥105.66 Million | CN¥339.50 Million | CN¥315.76 Million | CN¥210.10 Million | ▼ -10.9 pp |
| 2014 | 42.1% | CN¥132.65 Million | CN¥315.46 Million | CN¥247.01 Million | CN¥114.36 Million | ▲ +2.4 pp |
| 2013 | 39.7% | CN¥99.80 Million | CN¥251.50 Million | CN¥211.60 Million | CN¥111.80 Million | ▲ +8.0 pp |
| 2012 | 31.7% | CN¥65.17 Million | CN¥205.54 Million | CN¥231.62 Million | CN¥166.44 Million | ▼ -23.8 pp |
| 2011 | 55.5% | CN¥84.35 Million | CN¥151.87 Million | CN¥204.43 Million | CN¥120.07 Million | — |